How many institutions held ABUS - Arbutus Biopharma Corp - Common Shares, without par value in Q2 2018?

67 institutional investors reported ABUS - Arbutus Biopharma Corp - Common Shares, without par value for Q2 2018. Use the holders table for investor-level position and value details.

Arbutus Biopharma Corp - Common Shares, without par value (ABUS)

Q: What does CUSIP 03879J100 represent in this 13F holders report?

CUSIP 03879J100 is the security identifier for ABUS - Arbutus Biopharma Corp - Common Shares, without par value used to aggregate holder disclosures.

CUSIP: 03879J100

Q2 2018 13F Holders as of 30 Jun 2018

Type / Class: Equity / Common Shares, without par value
Shares outstanding: 194,990,877
Total 13F shares: 20,448,527
Share change: +2,096,044
Total reported value: $149,271,310
Put/Call ratio: 38%
Price per share: $7.30
Number of holders: 67
Value change: +$19,689,424
Number of buys: 44
Number of sells: 19

Quarterly Holders Quick Answers

What is CUSIP 03879J100?
CUSIP 03879J100 identifies ABUS - Arbutus Biopharma Corp - Common Shares, without par value in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q3 2018
Previous quarter: Q1 2018

Recent filing periods for CUSIP 03879J100:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of ABUS - Arbutus Biopharma Corp - Common Shares, without par value (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
RTW INVESTMENTS, LP	13F	Company	2.6%	5,151,615	$25,758,000	—	31 Mar 2018	13F
PRIMECAP MANAGEMENT CO/CA/	13F	Company	2.1%	4,000,400	$20,002,000	—	31 Mar 2018	13F
LADENBURG THALMANN FINANCIAL SERVICES INC.	13F	Company	0.91%	1,765,315	$8,827,000	—	31 Mar 2018	13F
Foresite Capital Management IV, LLC	13F	Company	0.76%	1,485,245	$7,426,000	—	31 Mar 2018	13F
BANK OF MONTREAL /CAN/	13F	Company	0.45%	882,423	$4,412,000	—	31 Mar 2018	13F
D. E. Shaw & Co., Inc.	13F	Company	0.36%	710,462	$3,552,000	—	31 Mar 2018	13F
BlackRock Finance, Inc.	13F	Company	0.35%	689,906	$3,450,000	—	31 Mar 2018	13F
AXA S.A.	13F	Company	0.27%	535,644	$2,678,000	—	31 Mar 2018	13F
MORGAN STANLEY	13F	Company	0.26%	513,996	$2,570,000	—	31 Mar 2018	13F
Hudson Bay Capital Management LP	13F	Company	0.18%	360,000	$1,800,000	—	31 Mar 2018	13F
ASCEND CAPITAL, LLC	13F	Company	0.15%	290,720	$1,454,000	—	31 Mar 2018	13F
OXFORD ASSET MANAGEMENT LLP	13F	Company	0.13%	253,746	$1,269,000	—	31 Mar 2018	13F
RENAISSANCE TECHNOLOGIES LLC	13F	Company	0.12%	243,500	$1,218,000	—	31 Mar 2018	13F
JPMORGAN CHASE & CO	13F	Company	0.11%	222,329	$1,112,000	—	31 Mar 2018	13F
BAKER BROS. ADVISORS LP	13F	Company	0.09%	180,582	$903,000	—	31 Mar 2018	13F
VICTORY CAPITAL MANAGEMENT INC	13F	Company	0.09%	167,150	$836,000	—	31 Mar 2018	13F
K2 PRINCIPAL FUND, L.P.	13F	Company	0.08%	151,078	$755,000	—	31 Mar 2018	13F
Eversept Partners, LP	13F	Company	0.06%	117,495	$587,475	—	31 Mar 2018	13F
GOLDMAN SACHS GROUP INC	13F	Company	0.05%	106,670	$533,000	—	31 Mar 2018	13F
PDT Partners, LLC	13F	Company	0.04%	72,500	$363,000	—	31 Mar 2018	13F
DEUTSCHE BANK AG\	13F	Company	0.03%	64,895	$324,000	—	31 Mar 2018	13F
CITADEL ADVISORS LLC	13F	Company	0.03%	64,797	$324,000	—	31 Mar 2018	13F
Telemetry Investments, L.L.C.	13F	Company	0.02%	45,000	$225,000	—	31 Mar 2018	13F
UBS Group AG	13F	Company	0.02%	41,965	$210,000	—	31 Mar 2018	13F
MACKENZIE FINANCIAL CORP	13F	Company	0.02%	39,900	$200,000	—	31 Mar 2018	13F
Deutsche Girozentrale DekaBank	13F	Individual	0.02%	34,500	$174,000	—	31 Mar 2018	13F
SCOTIA CAPITAL INC.	13F	Company	0.01%	29,050	$145,000	—	31 Mar 2018	13F
ProShare Advisors LLC	13F	Company	0.01%	25,453	$127,000	—	31 Mar 2018	13F
ROYAL BANK OF CANADA	13F	Company	0.01%	14,999	$75,000	—	31 Mar 2018	13F
A.R.T. Advisors, LLC	13F	Company	0.01%	14,491	$72,000	—	31 Mar 2018	13F
Seelaus Asset Management LLC	13F	Company	0.01%	14,300	$71,000	—	31 Mar 2018	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.01%	14,268	$71,000	—	31 Mar 2018	13F
STATE STREET CORP	13F	Company	0.01%	13,760	$69,000	—	31 Mar 2018	13F
Squarepoint Ops LLC	13F	Company	0.01%	13,300	$67,000	—	31 Mar 2018	13F
MILLENNIUM MANAGEMENT LLC	13F	Company	0.01%	13,207	$66,000	—	31 Mar 2018	13F
Spark Investment Management LLC	13F	Company	0.01%	12,000	$60,000	—	31 Mar 2018	13F
SIMPLEX TRADING, LLC	13F	Company	0%	7,031	$35,000	—	31 Mar 2018	13F
CITIGROUP INC	13F	Company	0%	3,686	$18,000	—	31 Mar 2018	13F
BANK OF AMERICA CORP /DE/	13F	Company	0%	3,115	$16,000	—	31 Mar 2018	13F
WELLS FARGO & COMPANY/MN	13F	Company	0%	3,001	$15,000	—	31 Mar 2018	13F
Tower Research Capital LLC (TRC)	13F	Company	0%	2,548	$13,000	—	31 Mar 2018	13F
Federation Des Caisses Desjardins du Quebec	13F	Individual	0%	800	$4,000	—	31 Mar 2018	13F
Cutler Group LLC / CA	13F	Company	0%	500	$2,000	—	31 Mar 2018	13F
Daiwa Securities Group Inc.	13F	Company	0%	304	$2,000	—	31 Mar 2018	13F
BARCLAYS PLC	13F	Company	0%	132	$1,000	—	31 Mar 2018	13F
CREATIVE FINANCIAL DESIGNS INC /ADV	13F	Company	0%	120	$1,000	—	31 Mar 2018	13F
Sonora Investment Management, LLC	13F	Company	0%	20	$100	—	31 Mar 2018	13F

Institutional Holders of Arbutus Biopharma Corp - Common Shares, without par value (ABUS) as of Q2 2018

As of 30 Jun 2018, Arbutus Biopharma Corp - Common Shares, without par value (ABUS) was held by 67 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 20,448,527 shares. The largest 10 holders included RTW INVESTMENTS, LP, PRIMECAP MANAGEMENT CO/CA/, Foresite Capital Management IV, LLC, BlackRock Inc., BANK OF MONTREAL /CAN/, MORGAN STANLEY, STATE STREET CORP, D. E. Shaw & Co., Inc., GOLDMAN SACHS GROUP INC, and NORTHERN TRUST CORP. This page lists 67 institutional shareholders reporting positions in this security for the Q2 2018 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q2 2018 vs Q1 2018 Across Filers

Q1 2018 holders

Q2 2018 holders

Holder diff

Investor	Q1 2018 Shares	Q2 2018 Shares	Share Diff	Share Chg %	Q1 2018 Value $	Q2 2018 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.